Toxicity results and early outcome data on a randomized phase II study of docetaxel ± bevacizumab for locally advanced, unresectable breast cancer.

ASCO SIGN IN

Username:

Create an account

Why Be A Member?

Password:

Remember me

Forgot your username or password?

The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

ASCO Home

Meetings

Abstracts

2006 ASCO Annual Meeting

Toxicity results and early outcome data on a randomized phase II study of docetaxel ± bevacizumab for locally advanced, unresectable breast cancer.

Sub-category:

Antiangiogenic or Antimetastatic agents

Category:

Developmental Therapeutics: Molecular Therapeutics

Meeting:

2006 ASCO Annual Meeting

Session Type and Session Title:

General Poster Session, Developmental Therapeutics: Molecular Therapeutics

Abstract No:

3049

Citation:

Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 3049

Author(s):

J. A. Lyons, P. Silverman, S. Remick, H. Chen, R. Leeming, R. Shenk, P. Fu, L. Dumadag, K. Escuro, B. Overmoyer

Abstract:

Background: Preclinical models of combination angiogenesis inhibitor bevacizumab (rhuMAbVEGF) and docetaxel demonstrate synergistic suppression of capillary vessel formation. Based upon these data, we developed a randomized phase II trial in order to evaluate the vascular effects on tumor regression with combination bevacizumab/docetaxel vs. docetaxel in the treatment of locally advanced breast cancer. Methods: 49 patients (pts) were randomized to receive neoadjuvant therapy with bevacizumab (10 mg/kg qowk) and docetaxel (two 8-week cycles of 35 mg/m² weekly x 6 with a 2 wk break) (BD=24) or docetaxel (D=25) alone. Eligible pts had locally unresectable breast cancer with (n=6) or without distant metastasis (n=43); 16 patients presented with inflammatory breast cancer. Pts whose disease responded, sequentially underwent definitive surgery (4 weeks after BD or D), radiation, 4 cycles of conventional Adriamycin/cyclophosphamide, and tamoxifen or anastrazole (if ER/PR+). Results: Among the 49 pts: 7 clinical CRs, 32 PRs, 5 NR, and 5 PD. Of the 37 pts who underwent surgery: the median number of pathologically positive lymph nodes (LN) was 1 (BD=6, D=1; p=0.228); range 0-20; 43% were LN negative. Neoadjuvant treatment toxicity for both arms was acceptable with no significant differences between the two arms. Grade 4 toxicity included BD - new papillary thyroid cancer (1), neutropenia (1), hyperuricemia (1) and colon perforation (1); and D: - hyperglycemia (1) and hyperuricemia (1). 21 patients in each arm experienced a grade 3 toxicity. There were no episodes of uncontrolled hypertension, proteinuria, or thrombosis. Delayed wound healing (unable to start radiation w/in 6 weeks of surgery) occurred in 8 pts: BD=5; D=3 (p=0.691). Only 1 pt (D) experienced a change in LVEF by > 15% or below the institution's lower limit of normal. Conclusions: Neoadjuvant therapy for locally advanced breast cancer using docetaxel with bevacizumab is well tolerated. Further studies are required to determine the added efficacy from bevacizumab. Correlative studies on impact of treatment on angiogenesis will be reported separately. (Sponsored by grants: K23CA 87725-01, M01 RR 00080, UO1 CA 62502, 5P30 CA43703-NCI/AVON, Aventis)

Associated Presentation(s):

1. Toxicity results and early outcome data on a randomized phase II study of docetaxel ± bevacizumab for locally advanced, unresectable breast cancer.

Meeting: 2006 ASCO Annual Meeting
Presenter: Janice A Lyons
Session: Developmental Therapeutics: Molecular Therapeutics (General Poster Session)

Other Abstracts in this Sub-Category:

		1. An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 1 in a 4 week on, 2 week off schedule in patients with advanced solid tumors. Meeting: 2006 ASCO Annual Meeting Abstract No: 2034 First Author: F. A. Eskens Category: Developmental Therapeutics: Molecular Therapeutics - Antiangiogenic or Antimetastatic agents
		2. Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway. Meeting: 2006 ASCO Annual Meeting Abstract No: 2035 First Author: M. L. Maitland Category: Developmental Therapeutics: Molecular Therapeutics - Antiangiogenic or Antimetastatic agents
		3. A phase I dose-escalation and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced cancer. Meeting: 2006 ASCO Annual Meeting Abstract No: 2048 First Author: S. Leong Category: Developmental Therapeutics: Molecular Therapeutics - Antiangiogenic or Antimetastatic agents
		More...

Abstracts by J. A. Lyons:

1. Toxicity results and early outcome data on a randomized phase II study of docetaxel ± bevacizumab for locally advanced, unresectable breast cancer.

Meeting: 2006 ASCO Annual Meeting Abstract No: 3049 First Author: J. A. Lyons
Category: Developmental Therapeutics: Molecular Therapeutics - Antiangiogenic or Antimetastatic agents

More...

Presentations by J. A. Lyons:

1. Toxicity results and early outcome data on a randomized phase II study of docetaxel ± bevacizumab for locally advanced, unresectable breast cancer.

Meeting: 2006 ASCO Annual Meeting
Presenter: Janice A Lyons
Session: Developmental Therapeutics: Molecular Therapeutics (General Poster Session)

More...

Educational Book Manuscripts by J. A. Lyons:

No items found.